| 08:30-10:00 |
Session 1 |
| Hall A |
LAPARASCOPIC SURGERY: NEW HORIZONS |
| Chairperson: |
A. Alcaraz, Spain |
| |
|
| 08:30-09:15 |
Debate: Advancing future Minimally Invasive Surgery
Single Port Access (SPA)/Laparo-Endoscopic Single Sight (LESS) and its role in the era of Natural Orifice Transluminal Endoscopic Surgery (NOTES)
A. Alcaraz, Spain
E. Lima, Portugal
|
| |
|
| 09:15-10:00 |
Debate: Controversies in Laparoscopic Training formats with the prospective development of Minimally Invasive Surgery
Controversies in Teaching of Laparoscopy
T. Piechaud, France
Teaching Laparoscopy - The innovative approach
R. Bollens, Belgium
|
| |
|
| 08:30-10:00 |
Session 2 |
| Hall B |
PROSTATE CANCER: NEW INSIGHTS TO MINIMAL AND LOCALIZED DISEASE
WHO IS AT RISK? |
| Chairpersons: |
L. Boccon-Gibod, France
Z. Kirkali, Turkey |
| |
|
| Capsule: |
Do we have the tools to determine who is at risk?
|
|
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:40
09:40-10:00 |
Genetic markers for prostate cancer
Y. Fradet, Canada
Obesity and prostate cancer: A myth or a threat
J. Pinthus, Canada
Histopathological grading of prostate cancer detected by biopsy: How reliable is it?
Liliane Boccon-Gibod, France
Nomograms and predicting tables: Pros and cons
Pro: F. Montorsi, Italy
Con: V. Hupertan, France
Who is a candidate for active surveillance?
Do we have clinical tools that make active surveillance safe?
What should be the follow-up?
L. Boccon-Gibod, Frace
N. Fleshner, Canada
|
| |
|
| |
|
| 10:00-10:30 |
Coffee Break and Poster Viewing |
| |
|
| 10:30-12:00 |
Session 3 |
| Hall A |
THE GREAT BLADDER WALL THICKNESS DEBATE:
TEARING IT DOWN, BRICK BY BRICK |
| Chairperson: |
J. Heesakkers, The Netherlands |
| |
|
10:30-11:00
11:00-11:30
11:30-12:00 |
A thick bladder wall is caused by functional obstruction during voiding
Pro: J. Ruiz Cerda, Spain
Con: D. Robinson, UK
Bladder wall thickness is too difficult to measure
Pro: F. Cruz, Portugal
Con: M. Oelke, Germany
Bladder wall thickness in OAB: Does it have a role?
Pro: V. Khullar, UK
Con: A. Tubaro, Italy |
| |
|
| 10:30-12:00 |
Session 4 |
| Hall B
|
ADVANCES IN THE MANAGEMENT OF METASTATIC RENAL CELL CANCER |
| Chairperson: |
C. Sternberg, Italy
|
| Capsule: |
Has the approach to the treatment of metastatic kidney cancer changed?
|
|
Welcome & Introduction |
| |
|
|
Case-based presentation:
Creating the Treatment Paradigm for Metastatic Renal Cell Cancer:
Does the Phase III evidences tell us what are the most appropriate options for our patients?
J. Bellmunt, Spain
V. Grunwald, Germany
P. Mulders, The Netherlands
J. Larkin, UK |
| |
|
| |
Combination vs. Sequential Therapy in Metastatic Renal Cell Cancer:
What does the evidences so far?
Pro: J. Bellmunt, Spain
V. Grunwald, Germany
Con: P. Mulders, The Netherlands
J. Larkin, UK |
| |
|
| |
Q&A & Closing |
| |
|
| 12:00-13:30 |
Session 5 |
| Hall A |
SATELLITE SYMPOSIUM:
HORMONE THERAPY FOR PROSTATE CANCER: EXPLORING CURRENT CONTROVERSIES |
| Chairperson: |
F. Montorsi, Italy
|
|
Introduction
F. Montorsi, Italy
What is the added value of (neo) adjuvant hormone therapy?
J. Irani, France
Continuous or intermittent hormone therapy in advanced prostate cancer?
C. Schulman, Belgium
Quality of life of prostate cancer patients on hormone therapy: Do we care enough?
R. Berges, Germany
Discussion and take-home messages
F. Montorsi
Faculty and participants
|
| |
|
| |
|
|
13:30-14:30 |
Lunch Break and Poster Viewing |
| |
|
| 14:30-16:00 |
Session 6 |
| Hall A |
KEY DECISIONS IN THE MANAGEMENT OF LUTS/BPH |
| Chairperson: |
F. Debruyne, The Netherlands |
| |
|
| Capsule: |
Does the clinical practice of LUTS/BPH treatment differ from that of guidelines and text books?
|
|
14:30-15:00
15:00-15:30
15:30-16:00 |
Who to treat and who not to treat?
Update lecture: F. Desgrandchamps, France
Case discussion: Chairman & Audience
Are there still indications for minimally invasive and surgical treatment?
Update lecture: B. Parada, Portugal
Case discussion: Chairman & Audience
Medical therapy: How to select the right patient for the right treatment?
Update lecture: M. Speakman, UK
Case discussion: Chairman & Audience
|
| |
|
| 14:30-16:00 |
Session 7 |
| Hall B |
MEET THE EXPERTS:
AN INSTRUCTIVE CASE DISCUSSION ON BLADDER CANCER |
| Chairpersons: |
A. Borkowski, Poland
A. Zlotta, Canada |
| |
|
| Capsule: |
Are we able to suppress the invasive nature of non-muscle invasive bladder tumors?
|
|
14:45-15:00
15:00-15:15 |
Debate: Maintenance therapy
How many and for how long?
A. Zlotta, Canada
Is maintenance therapy indicated for CIS?
Pro: J. Palou, Spain
Con: Z. Kirkali, Turkey
|
| |
|
|
15:15-16:00 |
Case discussion: High-grade T1 Bladder Cancer
The role of re-TUR
Prognostic factors
Optimizing efficacy of bladder irrigation
Presenter: A. Zlotta, Canada
Panel debaters:
Z. Kirkali, Turkey
O. Nativ, Israel
F. Witjes, The Netherlands
|
| |
|
| |
|
| 16:00-16:30 |
Coffee Break and Poster Viewing |
| |
|
| 16:30-18:00 |
Session 8 |
| Hall A |
SATELLITE SYMPOSIUM:
RECURRENT URINARY TRACT INFECTIONS: URO-VAXOM® A NEW ALTERNATIVE |
| Chairmen: |
F. Cruz, Portugal
M. Dambros, Brazil |
|
|
|
Opening
F. Cruz, Portugal
EAU guidelines on recurrent UTIs
K. Naber. Germany
Controversy discussion
Moderator: M. Dambros, Brazil
From science to clinical practice: The place of oral immunotherapy and Uro-Vaxom® in clinical practice
H.W. Bauer, Germany
From guidelines to clinical practice: What do we need? What is missing?
K. Naber, Germany
Uro-Vaxom® future developments: An update on the clincal plan
G. Cozma, OM PHARMA, Switzerland
|
| |
|
| 16:30-18:00 |
Session 9 |
| Hall B |
SATELLITE SYMPOSIUM:
TESTOSTERONE DEFICIENCY: A COMMON UNRECOGNIZED SYNDROME? |
| Chairperson: |
C. Schulman, Belgium
|
|
Transversal European survey on testosterone deficiency diagnosis
TESTO Dia: The first results
J. Tostain, France
Why should we have to treat?
Testosterone and metabolic syndrome
M. Zitzmann, Germany
Testosterone and erectile dysfunction
P. Vendeira, Portugal
Testosterone and prostate cancer
Is there any link?
A. Martin Morales, Spain
New perspectives on testosterone treatment
V. Mirone, Italy
|
| |
|
| 18:00-18:30 |
CURy Happy Hour |
WebStudio.co.il